JP2022521851A - 眼の病態に対する遺伝子療法 - Google Patents

眼の病態に対する遺伝子療法 Download PDF

Info

Publication number
JP2022521851A
JP2022521851A JP2021559062A JP2021559062A JP2022521851A JP 2022521851 A JP2022521851 A JP 2022521851A JP 2021559062 A JP2021559062 A JP 2021559062A JP 2021559062 A JP2021559062 A JP 2021559062A JP 2022521851 A JP2022521851 A JP 2022521851A
Authority
JP
Japan
Prior art keywords
eye
therapeutic product
condition
pathology
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021559062A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521851A5 (https=
Inventor
ダノス オリビエ
バン エベレン シェリー
アイ． ユー ジェシー
マガンバイ パテル サミール
アービンド ガネカル アバンティ
レイ オーベリー アンソニー
リース アーウィン‐パック キム
トーマス カーティス ダリン
Original Assignee
レジェンクスバイオ インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レジェンクスバイオ インコーポレーテッド filed Critical レジェンクスバイオ インコーポレーテッド
Publication of JP2022521851A publication Critical patent/JP2022521851A/ja
Publication of JP2022521851A5 publication Critical patent/JP2022521851A5/ja
Priority to JP2025083822A priority Critical patent/JP2025131621A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/04—Uses of viruses as vector in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2021559062A 2019-04-03 2020-04-02 眼の病態に対する遺伝子療法 Pending JP2022521851A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025083822A JP2025131621A (ja) 2019-04-03 2025-05-20 眼の病態に対する遺伝子療法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962828949P 2019-04-03 2019-04-03
US62/828,949 2019-04-03
US201962856533P 2019-06-03 2019-06-03
US62/856,533 2019-06-03
US201962946158P 2019-12-10 2019-12-10
US62/946,158 2019-12-10
PCT/US2020/026356 WO2020206098A1 (en) 2019-04-03 2020-04-02 Gene therapy for eye pathologies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025083822A Division JP2025131621A (ja) 2019-04-03 2025-05-20 眼の病態に対する遺伝子療法

Publications (2)

Publication Number Publication Date
JP2022521851A true JP2022521851A (ja) 2022-04-12
JP2022521851A5 JP2022521851A5 (https=) 2023-04-11

Family

ID=70480820

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021559062A Pending JP2022521851A (ja) 2019-04-03 2020-04-02 眼の病態に対する遺伝子療法
JP2025083822A Pending JP2025131621A (ja) 2019-04-03 2025-05-20 眼の病態に対する遺伝子療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025083822A Pending JP2025131621A (ja) 2019-04-03 2025-05-20 眼の病態に対する遺伝子療法

Country Status (13)

Country Link
US (1) US20220143221A1 (https=)
EP (2) EP4667578A3 (https=)
JP (2) JP2022521851A (https=)
KR (2) KR20220004987A (https=)
CN (2) CN113966236A (https=)
AU (1) AU2020253462A1 (https=)
BR (1) BR112021019825A2 (https=)
CA (1) CA3135843A1 (https=)
IL (1) IL286825A (https=)
MX (1) MX2021011889A (https=)
SG (1) SG11202110789VA (https=)
TW (1) TW202102679A (https=)
WO (1) WO2020206098A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201808426XA (en) 2016-04-15 2018-10-30 Univ Pennsylvania Compositions for treatment of wet age-related macular degeneration
EP3727468A4 (en) 2017-12-19 2021-09-22 Akouos, Inc. AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR
US12558434B2 (en) 2018-02-20 2026-02-24 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
CA3136119A1 (en) * 2019-04-10 2020-10-15 University Of Utah Research Foundation Htra1 modulation for treatment of amd
EP3752524A4 (en) * 2019-04-27 2021-11-24 Ocugen, Inc. ADENO-ASSOCIATED VIRUS VECTOR MEDIATED GENE THERAPY FOR OPHTHALMIC DISEASE
US20230277685A1 (en) * 2020-04-08 2023-09-07 President And Fellows Of Harvard College TGFß THERAPY FOR OCULAR AND NEURODEGENERATIVE DISEASES
CN111826386B (zh) * 2020-07-30 2022-02-01 西南大学 一种调控棉花纤维呈色的融合基因及其表达载体和应用
AU2021358781A1 (en) * 2020-10-07 2023-05-18 Tern Therapeutics, Llc Gene therapy for ocular manifestations of cln2 disease
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
CN116964209A (zh) * 2021-02-12 2023-10-27 格雷菲克斯公司 视网膜疾病的基因治疗
US20240316219A1 (en) * 2021-05-03 2024-09-26 North Carolina State University Compositions and methods related to the treatment of ocular diseases in equines
JP2024525183A (ja) * 2021-06-18 2024-07-10 イカロベック リミテッド 網膜障害
JP2025503637A (ja) * 2022-01-09 2025-02-04 クリヤ セラピューティクス， インコーポレイテッド 治療用抗ｉｇｆ－１ｒ抗体をコードする核酸の送達のためのベクター構築物およびそれを使用する方法
CN115137553A (zh) * 2022-07-11 2022-10-04 上海市同济医院 一种免造孔视网膜下液排出装置
JPWO2024048688A1 (https=) * 2022-08-31 2024-03-07
IL319873A (en) 2022-09-30 2025-05-01 Regenxbio Inc Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB
CN116965768B (zh) * 2023-07-07 2024-01-19 中山大学中山眼科中心 一种自动定量分析眼内前房炎症程度的系统
WO2026011181A1 (en) * 2024-07-05 2026-01-08 Wisconsin Alumni Research Foundation Design and application of novel photoreceptor-specific promoters for retinal gene therapy applications

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009531298A (ja) * 2006-02-22 2009-09-03 アイサイエンス・インターベンショナル・コーポレーション 脈絡膜上薬物送達のための装置および製剤
JP2014525930A (ja) * 2011-08-16 2014-10-02 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 被験者における眼疾患の処置のための方法および薬学的組成物
JP2016026182A (ja) * 2010-04-12 2016-02-12 株式会社アールテック・ウエノ 網膜疾患を処置するための方法および眼科用組成物
JP2017526478A (ja) * 2014-09-11 2017-09-14 ヤンセン・バイオテック・インコーポレイテッドＪａｎｓｓｅｎ Ｂｉｏｔｅｃｈ， Ｉｎｃ． 治療薬の電動式脈絡膜上腔注入
WO2017181021A1 (en) * 2016-04-15 2017-10-19 Regenxbio Inc. Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
WO2019067540A1 (en) * 2017-09-27 2019-04-04 Regenxbio Inc. TREATMENT OF OCULAR DISEASES WITH A TOTALLY HUMAN POST-TRANSLATIONAL MODIFICATION ANTI-VEGF FAB

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US878575A (en) 1906-12-31 1908-02-11 Isaac Stevenson Ore dredging and separating apparatus.
EP0804561B1 (en) 1993-02-12 2009-12-30 The Board Of Trustees Of The Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
AU719001B2 (en) 1994-12-29 2000-05-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
WO1996041865A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events
JP2003524368A (ja) 1997-08-26 2003-08-19 アリアド ジーン セラピューティクス インコーポレイテッド ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白
JP2001514007A (ja) 1997-08-27 2001-09-11 アリアド ジーン セラピューティクス インコーポレイテッド キメラ転写アクチベーター、ならびにそれに関連する組成物および使用
JP2002508971A (ja) 1998-01-15 2002-03-26 アリアド・ジーン・セラピューティクス・インコーポレーテッド 多量体キメラ蛋白質を使用する生物学的イベントの調節
JP2002503667A (ja) 1998-02-13 2002-02-05 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 新規な二量体化剤、その製造および使用
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
MX359371B (es) 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
PT1453547T (pt) 2001-12-17 2016-12-28 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
US20040208847A1 (en) * 2003-03-28 2004-10-21 Fabienne Rolling Method and vectors for selectively transducing retinal pigment epithelium cells
EP2345731B1 (en) 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
ES2525067T3 (es) 2005-04-07 2014-12-17 The Trustees Of The University Of Pennsylvania Método de incremento de la función de un vector de AAV
JP4495210B2 (ja) 2005-06-09 2010-06-30 パナソニック株式会社 振幅誤差補償装置及び直交度誤差補償装置
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
WO2012057363A1 (ja) 2010-10-27 2012-05-03 学校法人自治医科大学 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
WO2012109570A1 (en) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
CN105755044A (zh) 2011-04-22 2016-07-13 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
ES2857773T5 (es) 2011-08-24 2024-06-04 Univ Leland Stanford Junior Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
WO2013170078A1 (en) 2012-05-09 2013-11-14 Oregon Health & Science University Adeno associated virus plasmids and vectors
US9393370B2 (en) 2012-05-24 2016-07-19 Altaviz Llc Viscous fluid injector
CA2905952A1 (en) 2013-03-13 2014-10-02 The Children's Hospital Of Philadelphia Adeno-associated virus vectors and methods of use thereof
ES2739288T3 (es) 2013-09-13 2020-01-30 California Inst Of Techn Recuperación selectiva
CN106232618A (zh) 2013-10-11 2016-12-14 马萨诸塞眼科耳科诊所 预测祖先病毒序列的方法及其用途
WO2015164757A1 (en) 2014-04-25 2015-10-29 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
CN107249522B (zh) 2014-09-19 2021-04-20 奥叙拉尔有限公司 眼科递送装置
US11071643B2 (en) 2014-11-28 2021-07-27 Visionisti Oy Ocular therapeutics tool
AU2016219789B2 (en) * 2015-02-20 2021-03-25 Fondazione Telethon Methods and compositions for treating genetic eye diseases
US11154420B2 (en) 2015-09-17 2021-10-26 Oxular Limited Ophthalmic injection device
GB201519086D0 (en) * 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
USD878575S1 (en) 2015-11-24 2020-03-17 Visionisti Oy Hand operated medical instrument
CA3010862A1 (en) * 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics
WO2017158365A2 (en) 2016-03-16 2017-09-21 Oxular Limited Ophthalmic delivery device and ophthalmic active agent containing compositions
SG11201808426XA (en) 2016-04-15 2018-10-30 Univ Pennsylvania Compositions for treatment of wet age-related macular degeneration
IL316926A (en) * 2017-05-11 2025-01-01 Univ Pennsylvania Gene therapy for neuronal ceroid lipofuscinosis
US11071824B2 (en) 2017-11-04 2021-07-27 Altaviz, Llc Injection devices and methods for making and using them
US10912883B2 (en) 2017-11-04 2021-02-09 Altaviz, Llc Gas-powered fluid injection system
JP2022527116A (ja) * 2019-04-08 2022-05-30 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Ｔｐｐ１を発現するａａｖの投与による眼のリソソーム蓄積症の治療

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009531298A (ja) * 2006-02-22 2009-09-03 アイサイエンス・インターベンショナル・コーポレーション 脈絡膜上薬物送達のための装置および製剤
JP2016026182A (ja) * 2010-04-12 2016-02-12 株式会社アールテック・ウエノ 網膜疾患を処置するための方法および眼科用組成物
JP2014525930A (ja) * 2011-08-16 2014-10-02 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 被験者における眼疾患の処置のための方法および薬学的組成物
JP2017526478A (ja) * 2014-09-11 2017-09-14 ヤンセン・バイオテック・インコーポレイテッドＪａｎｓｓｅｎ Ｂｉｏｔｅｃｈ， Ｉｎｃ． 治療薬の電動式脈絡膜上腔注入
WO2017181021A1 (en) * 2016-04-15 2017-10-19 Regenxbio Inc. Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
WO2019067540A1 (en) * 2017-09-27 2019-04-04 Regenxbio Inc. TREATMENT OF OCULAR DISEASES WITH A TOTALLY HUMAN POST-TRANSLATIONAL MODIFICATION ANTI-VEGF FAB

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIODRUGS, 2006, 20 (3), PP. 167-179, JPN6022015792, ISSN: 0005295708 *

Also Published As

Publication number Publication date
US20220143221A1 (en) 2022-05-12
EP4667578A3 (en) 2026-04-01
TW202102679A (zh) 2021-01-16
KR20260033621A (ko) 2026-03-10
CN113966236A (zh) 2022-01-21
CN121371216A (zh) 2026-01-23
WO2020206098A1 (en) 2020-10-08
BR112021019825A2 (pt) 2021-12-21
AU2020253462A1 (en) 2021-10-28
EP4667578A2 (en) 2025-12-24
SG11202110789VA (en) 2021-10-28
KR20220004987A (ko) 2022-01-12
EP3946467A1 (en) 2022-02-09
WO2020206098A9 (en) 2021-02-04
JP2025131621A (ja) 2025-09-09
MX2021011889A (es) 2021-10-26
IL286825A (en) 2021-10-31
CA3135843A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
JP2022521851A (ja) 眼の病態に対する遺伝子療法
US20230057519A1 (en) Treatment of Ocular Diseases with Fully-Human Post-Translationally Modified Anti-VEGF Fab
US20250320287A1 (en) TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF Fab
US20220280608A1 (en) Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab
TW202228649A (zh) 諸如形成聚集體之調配物之用於脈絡膜上投與之調配物
US20260034250A1 (en) Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230330

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241002

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250121